Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPUS-1 phase 3 study of cenerimod in moderate-to-severe systemic lupus erythematosus
jRCT2031250226Phase 3Recruiting
- Sponsor
- Viatris
- Start
- Oct 2025
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Cenerimod + background therapy with Placebo + background therapy (2 arms). Primary endpoint: SRI-4 response at Month 12. Started Oct 2025; status: recruiting.
02
Drugs
cenerimod
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on jRCT2031250226.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250226.